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There has been a marked improvement in the treatment of rheu-
matoid arthritis (RA), but most patients do not achieve disease
remission. Therefore, there is still a need for new treatments. By
screeninganadenoviral shorthairpinRNA library,wediscovered that
knockdown of the nicotinic acetylcholine receptor type 7 (a7nAChR)
in RA ﬁbroblast-like synoviocytes results in an increased production
of mediators of inﬂammation and degradation. The a7nAChR is
intimately involved in the cholinergic anti-inﬂammatory pathway
(CAP). This led us to study the effects of a7nAChR activation in an
animalmodel of RA, andwe could show that this resulted in reduced
arthritis activity. Accordingly, stimulation of the CAP by vagus nerve
stimulation improved experimental arthritis. Conversely, we found
aggravation of arthritis activity after unilateral cervical vagotomy as
well as ina7nAChR-knockoutmice. Together, thesedataprovided the
basis for exploration of vagus nerve stimulation in RA patients as a
novel anti-inﬂammatory approach.
© 2014 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Immunology and Rheumatology, Room F4-105, Academic Medical Center,
msterdam, The Netherlands. Tel.: þ31 20 566 7765; fax: þ31 20 691 9658.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease, which is characterized by pain, swelling,
andstiffnessof joints, due to synovial inﬂammation.Duringactivedisease, the joints are limited inmotion
and function, and persistence of synovial inﬂammation leads to the development of bone erosions and,
ﬁnally, joint deformities [1]. The signs and symptoms of this condition can be reduced by treatmentwith
synthetic andbiological disease-modifying antirheumatic drugs (sDMARDs andbDMARDs, respectively).
Treatment of RA is usually initiated with methotrexate, a sDMARD, and can be combined with cortico-
steroids and other sDMARDs. Biological DMARDs are indicated if there is insufﬁcient response to the
initial sDMARD treatment or if there are unfavorable prognostic factors present, such as very active
disease, early joint damage, or presence of (high levels) of autoantibodies, immunoglobulin M (IgM)
rheumatoid factor (RF), and/oranti-citrullinatedproteinantibodies (ACPAs) [2].Despite the fact that there
are many types of DMARDs available, there are still many RA patients who do not improve sufﬁciently.
Besides the lack of response to therapy as a reason for the discontinuation of treatment, there are also
patientswho discontinuemedication because of side effects, or because they do notwant to take chronic
medication. As a result, the need for the development of new therapeutic strategies remains.
Cholinergic anti-inﬂammatory pathway
Inﬂammation in peripheral tissues, as observed in RA, can be detected by the afferent vagus nerve and
this information is signaled towards the brain. Peripheral administration of the pro-inﬂammatory medi-
ators lipopolysaccharide (LPS) or interleukin-1-beta (IL1-beta) in rats normally elicits fever, but after
bilateral subdiaphragmatic vagotomy the fever response is abated [3,4]. Later, there was the surprising
ﬁnding that the vagusnerve couldnot only sense inﬂammation but also inﬂuence it. Activationof the vagus
nerve, which is a part of the parasympathetic nervous system, was found to dampen inﬂammatory pro-
cesses. Rats with carrageenan-induced hind paw edema (acute inﬂammation model) were injected
intracerebroventricularly (i.c.v) with a very low dose (noneffective if given systemically [3]) of the anti-
inﬂammatory drug CNI-1493, and there was a signiﬁcant decrease in paw edema. The anti-inﬂammatory
mechanism of action of i.c.v. CNI-1493 was, at the time, unknown, but after bilateral cervical vagotomy
the drugwas no longer able to reduce pawedema. In combinationwith theﬁnding that an i.c.v. injection of
CNI-1493, but not saline, could increase efferent vagus nerve activity, this led to the conclusion that acti-
vation of the vagus nerve by i.c.v. CNI-1493 treatment had an anti-inﬂammatory effect [5]. These were the
ﬁrst indications that efferent vagus nerve activation could inhibit inﬂammation in an animal model. The
combination of sensing peripheral inﬂammation by the afferent vagus nerve and the subsequent anti-
inﬂammatory response of the efferent vagus nerve is currently known as the cholinergic anti-
inﬂammatory pathway (CAP) [6].
TheCAPcanalsobeactivatedbyelectrical vagusnerve stimulation (VNS)or stimulationof thenicotinic
acetylcholine receptor type7 (a7nAChR) [7,8]. Theparasympatheticneurotransmitteracetylcholine is the
anti-inﬂammatorymediator of the CAP, which activates the a7nAChR. Acetylcholine can be produced by
the vagus nerve, but it can also be produced by nonneuronal cells, for instance, in the spleen. Several
studies have shown that the spleen is essential for the anti-inﬂammatory effect of the vagus nerve,
because after splenectomyVNS isno longer capableof reducing inﬂammation [9e12]. AfterVNS, the anti-
inﬂammatory reﬂex appears to travel through the sympathetic splenic nerve towards the spleen. The
splenicnerveproducesnorepinephrine,which triggers cholineacetyltransferase-positive (CHATþ) Tcells
in thespleen toproduceacetylcholine (Fig.1) [13,14]. CHAT-positive cells arealso found in the synoviumof
the RA joint [15,16], which suggests that acetylcholine can also be produced locally in the joint. Joints are
not known to be innervated by the vagus nerve, but there appear to be sympathetic ﬁbers in the RA
synovium [17]. It is, therefore, conceivable that norepinephrine-producing sympatheticﬁbers in the joint
activate CHATþ T cells to produce acetylcholine, but this has not been studied yet.
CAP in experimental arthritis
In the past decade, the anti-inﬂammatory effect of the vagus nerve has been shown in animal
models for sepsis, acute pancreatitis, colitis, postoperative ileus, and acute respiratory distress
Fig. 1. Electrical stimulation of the parasympathetic vagus nerve leads to activation of the sympathetic splenic nerve which produces
norepinephrine in close proximity to choline acetyltransferase positive (CHATþ) T-cells. The CHATþ T-cells are able to produce the
anti-inﬂammatory mediator acetylcholine, which can bind to the nicotinergic acetylcholine receptor type 7 (a7nAChR) and reduces
cytokine production. This results in reduced inﬂammation in the joints.
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speciﬁc agonist AR-R17779 [22] and the non-speciﬁc agonist nicotine [22,23] in an animal model of RA,
and demonstrated that this approach resulted in reduced clinical signs of arthritis, synovial inﬂam-
mation, serum cytokine levels, and bone erosions. These results have been conﬁrmed by others using
the partially speciﬁc agonist GTS-21 [24] and nicotine [23]. Conversely, we found a higher incidence of
arthritis and more severe arthritis in mice lacking the a7nAChR [25]. The a7nAChR is present not only
on many immune cell types, such as monocytes, macrophages, T lymphocytes, B lymphocytes, and
dendritic cells [26] but also on ﬁbroblast-like synoviocytes (FLSs) in the RA synovium [27,28]. FLSs of
RA patients pretreated with acetylcholine, nicotine, or AR-R17779 (a7nAChR activation) reduced the
production of IL-6 and IL-8 signiﬁcantly [27e29], indicating that acetylcholine could also have an anti-
inﬂammatory effect in the RA synovium. Besides FLSs, macrophages and monocytes also produce less
pro-inﬂammatory cytokines after a7nAChR activation [6,30]. Thus, human biology studies were in line
with the results obtained in animal models of RA, supporting the notion that stimulation of the CAP
could have a beneﬁcial effect in RA.
Stimulation of the CAP by electrical VNS is challenging in the experimental arthritis model, because
daily electrical stimulation is needed for a prolonged period rather than single electrical stimulation in
the acute mouse models. As an alternative approach, vagus suspension to the sternocleidomastoid
muscle was performed, leading to activation of the vagus nerve as a result of head movement, after
arthritis induction. This led to reduced arthritis activity, decreased serum levels of tumor necrosis
factor (TNF), and protection against bone destruction associated with a decrease in the number of
osteoclasts after 3 months of follow-up [31]. Whenwe applied electrical stimulation of the vagus nerve
for 60 s a day using an implanted vagus nerve stimulator in the collagen-induced arthritis model of RA
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as well as cartilage damage after 7 days of stimulation [32]. Taken together, activation of the CAP has a
consistent anti-inﬂammatory effect in experimental models of RA.
Effect of nicotine-containing substances in RA patients
As discussed above, nicotine can stimulate the CAP through activation of the a7nAChR. However,
despite cigarette smoking being a well-deﬁned risk factor for the development of RA [33e35], a
beneﬁcial effect of nicotine on experimental arthritis and an anti-inﬂammatory effect on RA FLS are
observed [22,23,27,28]. How can we reconcile these data? First, it is important to note that, obviously,
smoking of cigarettes results in exposure to many other compounds in addition to nicotine. In
particular, in RA patients who have a speciﬁc genetic background, being positive for the shared epitope,
smoking of cigarettes is associated with the development of ACPAs [35]. Indeed, several studies have
shown that RA patients who smoke cigarettes have higher disease activity compared to nonsmokers
[36e38], although not all data are conclusive [39e41]. The response to therapy in RA patients who are
current smokers is lower in most of the longitudinal cohort studies [38,42e45]. If the negative effect of
smoking of cigarettes is related to inhaling compounds other than nicotine, then lessons may be
learned from the use of nicotine-containing “snuff” (smokeless tobacco) in RA patients. Interestingly,
there was a lower disease activity in RA patients who used snuff compared to those who never smoke
and previous smokers [46]. Consistent with our hypothesis that substances in smoked tobacco other
than nicotine are associated with an increased risk of active RA in shared epitope-positive subjects, the
use of snuff is not associated with the development of RA [34,47]. Obviously, RA patients who are
current smokers should be advised to stop, also because of the increased risk of cardiovascular disease
and cancer associated with smoking [48,49]. The use of snuff is also not harmless, because it contains
carcinogenic substances and users have a higher risk of developing oral cancer and cardiovascular
disease [46]. However, the observations described above do support the notion that stimulation of the
CAP may result in a beneﬁcial effect on RA.
Activity of the parasympathetic nervous system in RA
The vagus nerve, the main component of the parasympathetic nervous system, is most active when
the body is in a resting state, and at that time it has a dominant inﬂuence on breathing, heart rate, and
digestion. In a more active “ﬂight” state, the sympathetic nervous system becomes dominant in con-
trolling these basic body functions. The balance in the autonomic nervous system can be measured by
measuring heart rate variability (HRV) [50]. Individuals with a normal HRV are able to respond
adequately to changes in blood pressure and breathing, and have therefore a well-functioning auto-
nomic nervous system. Various observational studies have demonstrated that RA patients have lower
vagus nerve tone shown by reduced HRV compared to age-matched controls [51e53]. This phenom-
enon has also been observed in other autoimmune diseases, such as systemic lupus erythematosus
[51], ankylosing spondylitis [54], and chronic inﬂammatory bowel diseases [55]. Parasympathetic
activity can be increased by different types of exercise, like cardiac training [56], yoga [57], meditation
[58], daily 5-min diaphragmatic breathing [59], and possibly acupuncture [60]. One study showed that
low parasympathetic and high sympathetic activity in RA patients predicts a poor therapeutic response
to anti-TNF therapy compared to RA patients with a more balanced autonomic nervous system [61].
Taken together, these data show that chronic inﬂammatory diseases are associated with reduced
parasympathetic and increased sympathetic activity. The autonomic balance could potentially be
restored by electrical stimulation of the vagus nerve.
VNS in patients with depression or epilepsy
VNS therapy has been approved as a treatment for epilepsy in Europe in 1994 and in the US in 1997
[62]; in the US, VNS has also been approved for the treatment of depression [63]. VNS can be performed
after neurosurgical implantation of a vagus nerve stimulator; in 2012, 100,000 vagus nerve stimulators
had been implanted [64]. The device consists of two parts: a pulse generator and a leadwith electrodes.
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below the left clavicle on the pectoral muscle. It is connected to the left vagus nerve in the neck via the
lead, with three helices at the end: one positive electrode, one negative electrode, and an anchor tether.
The three helices are placed around the vagus nerve to deliver the electrical pulse of the pulse
generator (Fig. 2A and B). During surgery, the vagus nerve is electrically stimulated to test the
impedance and functionality of the device, which can be accompanied by bradycardia and short-
lasting asystole, which is a rare adverse event occurring in about 0.1% of patients; it has only been
reported as a consequence of the ﬁrst stimulation during surgery and is resolved when stimulation is
stopped [65]. Adverse events after implantation include infections of the operated area (3e6% of pa-
tients) and vocal cord paresis (<1% of patients) [65]. After implantation, VNS therapy can be initiated
starting at a low dosage of stimulation with an output current of 0.25 mA. The dosage is increased
slowly with steps of 0.25 mA to a maximum output current of 3.5 mA, because toleration to the
stimulation is built up with use of the VNS device. However, the ﬁnal maximum tolerated dosage of the
patient can be lower than 3.5 mA. Other stimulation conditions that can be selected are pulse width
(130e1000 ms), frequency (10e30 Hz), and duration of stimulation (7e60 s). The VNS settings can be
changed with an external programmer and information about performed stimulations (compliance)
can be retrieved (Fig. 2C and D). During electrical stimulation, >10% of patients report hoarseness, soreFig. 2. Vagus nerve stimulation (VNS) from surgery to stimulation settings. A. Implantation of the three helices around on the left
vagus nerve containing a positive electrode, negative electrode and an anchor tether. The electrodes are connected to the lead, which
is attached to the pulse generator. B. Marks of the implantation 6 months after the operation. There are two incisions made to
implant the VNS device. The ﬁrst horizontal incision is made in the neck to implant the helices around the vagus nerve, the lead is
tunneled under the skin and connected to the pulse generator located below the left clavicle on the pectoral muscle, which requires
the second horizontal incision. C. With a wand above the pulse generator and a read-out handheld computer, the settings of the
pulse generator can be changed or stimulations can be evaluated. D. Example of stimulation settings on the handheld computer.
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symptoms do not require adjustments of VNS device settings [65]. Patients normally only experience
side effects if the VNS device is activated. Epilepsy patients receive stimulation several times per hour
(the standard setting is 30 s on/5 min off) and have the option to give an additional stimulation with a
magnet activation to prevent an upcoming seizure [66].
Early experience with VNS in RA patients
In 2011, we initiated an open pilot study on the safety and efﬁcacy of VNS in RA patients. The hy-
pothesis based on preclinical studies is that VNS will have a beneﬁcial effect on the clinical signs and
symptoms of RA. Patients were eligible for inclusion in the study if they were diagnosed with RA >6
months ago according to the American College of Radiology (ACR)/The European League Against
Rheumatism (EULAR) 2010 criteria and presented with active disease, deﬁned by the presence of at
least four swollen joints and C-reactive protein (CRP) levels 7 mg/L. Patients needed to be on stable
methotrexate treatment for at least 3 months and were not allowed to have failed bDMARD treatment.
The exclusion criteria of the study were mainly general contraindications for VNS therapy (Table 1).
At the time of study initiation, we expected that it would be difﬁcult to include RA patients in a study
evaluating a new therapy requiring surgery. However, an overwhelming number of patients responded
andwanted to participate in the clinical trial: we received around 1000 responses after the publication of
an article in a national newspaper in the Netherlands. Many patients indicated that theywere interested
inparticipating in the studyas they preferred aminor surgical procedure over chronic drug therapy. They
also liked the concept of restoring the natural balance in the body and the feeling of havingmore control
over their disease themselves. Three of these patients fulﬁlled all inclusion and exclusion criteria, had
sufﬁciently active disease (at least four swollen joints and CRP level 7 mg/L), and were included in the
pilot study at the Academic Medical Center (AMC) in Amsterdam. Other patients were included in the
following centers: University Clinical Hospital, Mostar; Clinical Hospital Center Sestre Milosrdnice,
Zagreb; and Sarajevo University Clinical Center, Sarajevo. In total, eight patients were included.
The design of the study is depicted in Fig. 3. Two weeks after implantation of the VNS device, VNS
was initiated at 0.5 mA once daily (QD), and this was increased upon toleration by the patient up to a
maximum of 2.00 mA during weekly visits. Patients triggered the 60-s stimulation themselves by
moving a strong magnet across the pulse generator. In the ﬁrst week at day 0, patients received their
ﬁrst stimulation and responses were evaluated 1, 2, 4, and 24 h and 4 days after stimulation. Daily home
stimulation was initiated at day 7, and until day 21 the stimulation intensity (output current) wasTable 1
In- and exclusion criteria of the vagus nerve stimulation study in rheumatoid arthritis (RA). The exclusion criteria of the study are
based on recommendations of Cyberonics™ for use of a Vagus Nerve Stimulation device.
Inclusion criteria
Rheumatoid arthritis of a duration of at least 6 months as deﬁned by the ACR/EULAR classiﬁcation criteria
Active disease, deﬁned by at least four swollen joints and CRP >7 mg/L
Active disease, despite treatment with methotrexate at a stable dose for at least 3 months
Previous failure to respond to bDMARD therapy is not allowed, but discontinuation of bDMARD for a different reason is
allowed
Exclusion criteria
Known history of cardiac rhythm disturbances, atrioventricular block > ﬁrst degree, or cardiac conduction pathway
abnormalities
Signiﬁcant pharyngeal dysfunction or swallowing difﬁculties
Preexisting clinically signiﬁcant vocal cord damage or hoarseness
Asthma or chronic obstructive pulmonary disease not controlled by medication, or any other disease causing signiﬁcant
dyspnea
Previously implanted electrically active medical devices
History of recurrent vasovagal syncope episodes
History of obstructive sleep apnea
Active peptic ulcer disease
Fig. 3. Overview of set-up of the open pilot study to evaluate the safety and initial efﬁcacy of VNS therapy in RA patients.
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EULAR criteria [67]; if the patient did not fulﬁll the response criteria, then the stimulation frequency
was increased from QD to four times daily (QID). Stimulations were continued until day 42 (primary
end point) and discontinued from day 42 until day 56 for 14 days. At day 56, stimulation was started
again at the previously set stimulation level (mA) and frequency (QD or QID) until day 84. After day 84,
patients were enrolled in an extension study, during which they continued VNS therapy. The primary
end point of the study was the change in DAS28 (CRP) at day 42 from baseline. Fulﬁllment of the ACR20
response criteriawas one of the secondary end points [68]. Therewere no serious adverse events in the
ﬁrst eight patients; there were 21 adverse events in seven patients, which were all mild or moderate.
Examples of adverse events were dry throat, hoarseness, dyspnea, numbness of skin on neck under the
jaw, and tingling in the scar area [69]. The clinical data in a larger group of patients are currently being
analyzed.
Advantages and disadvantages of VNS therapy of RA: could there be a place in the treatment of
RA?
As described above, there is over 15 years of safety information available about VNS therapy in
epilepsy and depression patients. The consistent preclinical data in experimental models of arthritis
and the wide experience with the implantation of the device and known side effects of VNS therapy
paved theway to initiate an exploratory clinical trial in RA patients, and for patients to participate.With
side effects occurring primarily during stimulation and a frequency of stimulation much lower
compared to that used in epilepsy, the burden of stimulation in RAwas expected to be low. Stimulation
was tolerated better every week and became part of the patients' daily routine. A downside of this
approach is that it requires ~1-h surgery, which entails certain risks during and after the operation as
described above in “VNS in patients.” It should also be noted that complete removal of the VNS system
is challenging, because of the formation of ﬁbrosis around the helices attached to the vagus nerve. As
not all patients will respond to therapy, it is important for patients to consider the risk of placement
and possible removal of the VNS device. It is, however, not necessary to have the VNS device removed if
the therapy failed, as it can also be deactivated. It is also worthmentioning that, when a VNS device has
been implanted, magnetic resonance imaging (MRI) can only be performed on some areas of the body
with speciﬁc settings. Areas that can be imaged include the knee joints, ankles, and the head, but MRI
of the chest is not possible when the device is in place as there is a risk of overheating the lead. This can
also occur with the use of therapeutic diathermy. MRI and diathermy restrictions are lifted after
complete removal of the VNS device, including the three helices around the vagus nerve [70]. The
positioning of VNS therapy in the treatment of RA will obviously depend on its effectiveness which is
currently unknown. If effective, many RA patients may prefer this approach as it is appealing based on
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nosuppressive treatment associated with possible side effects. It is conceivable that VNS therapy would
be more cost-effective than bDMARD therapy. The CyberonicsTM (Houston, Texas) VNS device used in
our clinical trial currently costs aroundV 9500 [71] and there are of course additional costs for surgery.
The VNS pulse generator (battery) has a life-span of around 7e10 years in epilepsy treatment, but
because of the lower frequency of stimulation it may have a longer life-span in RA patients. RA therapy
with bDMARD currently costs aroundV 15,000 per patient per year [72]. If VNS therapy can prevent the
need for bDMARD treatment, it starts to be cost-effective after around 1e1.5 year. Taken together, VNS
therapy has the potential to be a low-cost therapy compared to bDMARD therapy for RA patients if the
therapy has a long-term beneﬁcial effect.
Summary and future directions
Innovative therapies have been developed for the treatment of RA over the past decade, which have
greatly improved the disease outcome [73]. However, many patients continue to be unresponsive to
current treatment; therefore, there remains a need to develop new therapies. We have shown in
experimental models of RA that stimulation of the vagus nerve or activation of the CAP consistently has
an anti-inﬂammatory effect, leading to amelioration of arthritis, reduction in serum cytokine levels,
and protection against joint destruction. Electrical VNS therapy has been applied in epilepsy and
depression patients for >15 years. The preclinical studies and the experience with VNS in other in-
dications have paved the way for an experimental clinical trial using this approach in RA patients,
which is currently ongoing. If successful, the advantage of this approach could be that it is a safe, and
well-tolerated therapy, appealing to patients as it aims to restore the natural balance by targeting an
intrinsic anti-inﬂammatory pathway. VNS therapy should not lead to immunosuppression and can
therefore be combined with both sDMARDs and bDMARDs, nor does it have the problem of causing
development of anti-drug antibodies. The long life-span (7e10 years) of the VNS pulse generator will
make this approach cost-effective, if there is a prolonged therapeutic effect.Practice points
 The extensive knowledge about vagus nerve stimulation in epilepsy and depression patients
shows that it is generally a safe and well-tolerated therapy.
 VNS therapy is an appealing concept for patients, as it aims to restore the natural balance in
the body without the need for long-term immunosuppressive treatment associated with
possible side effects.
 The disadvantage of implantation of the VNS device is that it requires an ~1-h surgery and
that after implantation there are restrictions in performing MRI and therapeutic diathermy.
Research points
 Preclinical studies show that the cholinergic anti-inflammatory pathway, via activation of the
nicotinic acetylcholine receptor type 7 (a7nAChR) or by vagus nerve stimulation, has a
beneficial effect on synovial inflammation and protects against progressive joint damage.
Lack of the a7nAChR or abrogation of the vagus nerve has a detrimental effect on arthritis
activity in experimental models of RA.
 An open pilot study has been initiated to evaluate the short- and long-term safety and initial
efficacy of VNS therapy in RA patients
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